Autolus Therapeutics (AUTL) to Release Earnings on Thursday

Autolus Therapeutics (NASDAQ:AUTL) is expected to announce its Q4 2025 results before the market opens on Thursday, March 19th. Analysts expect the company to announce earnings of ($0.27) per share and revenue of $23.9160 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Friday, March 27, 2026 at 8:30 AM ET.

Autolus Therapeutics Stock Performance

Shares of NASDAQ AUTL opened at $1.51 on Wednesday. The firm has a market capitalization of $401.88 million, a price-to-earnings ratio of -1.82 and a beta of 1.95. The stock has a 50 day moving average price of $1.53 and a 200 day moving average price of $1.53. Autolus Therapeutics has a 52-week low of $1.11 and a 52-week high of $2.70.

Institutional Investors Weigh In On Autolus Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. Mak Capital One LLC raised its stake in Autolus Therapeutics by 15.3% during the fourth quarter. Mak Capital One LLC now owns 30,005,343 shares of the company’s stock worth $59,711,000 after purchasing an additional 3,987,727 shares during the period. Armistice Capital LLC grew its stake in shares of Autolus Therapeutics by 30.0% in the 3rd quarter. Armistice Capital LLC now owns 15,600,000 shares of the company’s stock valued at $25,428,000 after buying an additional 3,600,000 shares during the period. Schroder Investment Management Group increased its holdings in shares of Autolus Therapeutics by 12.5% during the 4th quarter. Schroder Investment Management Group now owns 9,489,345 shares of the company’s stock worth $18,694,000 after buying an additional 1,056,092 shares during the last quarter. Bank of America Corp DE raised its position in shares of Autolus Therapeutics by 108.1% during the 3rd quarter. Bank of America Corp DE now owns 2,029,593 shares of the company’s stock valued at $3,308,000 after buying an additional 1,054,458 shares during the period. Finally, Cetera Investment Advisers raised its position in shares of Autolus Therapeutics by 37.3% during the 4th quarter. Cetera Investment Advisers now owns 1,099,750 shares of the company’s stock valued at $2,189,000 after buying an additional 298,500 shares during the period. 72.83% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

AUTL has been the subject of a number of research analyst reports. Zacks Research raised Autolus Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Friday, March 13th. Weiss Ratings reissued a “sell (d-)” rating on shares of Autolus Therapeutics in a research report on Wednesday, January 21st. HC Wainwright initiated coverage on Autolus Therapeutics in a research note on Tuesday, February 17th. They set a “buy” rating and a $9.00 price target on the stock. Finally, Needham & Company LLC decreased their price objective on Autolus Therapeutics from $11.00 to $10.00 and set a “buy” rating for the company in a report on Monday, January 12th. Five analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $8.50.

About Autolus Therapeutics

Autolus Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of next-generation, programmed T cell therapies for the treatment of cancer. The company leverages proprietary technologies to engineer autologous T cells that target and eradicate tumor cells, with the aim of improving safety, efficacy and durability over existing cell therapies. Its R&D platform integrates antigen receptor design, gene editing and manufacturing optimization to generate candidates tailored for specific hematologic malignancies and solid tumor indications.

The company’s leading pipeline candidates include AUTO1, an optimized CD19-targeted CAR-T therapy for relapsed or refractory acute lymphoblastic leukemia, and AUTO3, a dual-targeted CD19/22 CAR-T program in development for diffuse large B-cell lymphoma.